Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID ‐19 pandemic in Italy
Authors:
- Luca StingeniLSLuca Stingeni
- Katharina HanselKHKatharina Hansel
- Giacomo Dal BelloGBGiacomo Dal Bello
- Cataldo PatrunoCataldo Patruno
- Maddalena NapolitanoMaddalena Napolitano
- Gabriella FabbrociniGabriella Fabbrocini
- Teresa GriecoTeresa Grieco
- Giovanni PellacaniGPGiovanni Pellacani
- Maria Concetta FargnoliMFMaria Concetta Fargnoli
- Maria EspositoMEMaria Esposito
- Viviana PirasVPViviana Piras
Open Access
- 21 June 2021
- journal article
- research article
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (5) , e15035
Abstract
Dupilumab showed significant improvement of adolescent atopic dermatitis (AD) signs and symptoms in clinical trials, with a good safety profile. Herein we report the real-word effectiveness and safety of dupilumab in adolescents with moderate to severe AD from January to October 2020, during the COVID-19 pandemic in Italy. All patients had a diagnosis of AD for a mean [SD] 12.8 [3.1] years. Baseline demographics, AD characteristics (EASI, cDLQI, NRS itch score, NRS sleep loss score) at baseline and week 16, and safety data were collected. Nineteen patients (52.6% men; mean [SD] age, 15.6 [1.4] years [range, 13–17 years]) were included in the analysis. All patients reached EASI-50 and 78.9% EASI-75, especially in those with EASI≥30 and BMI < 25 at baseline, with marked reduction for cDLQI (77.4%), NRS itch score (5.9 point), and NRS sleep loss score (87.5%). One patient contracted asymptomatic SARS-CoV-2 infection and 1 developed mild conjuntivitis, without stopping dupilumab. In this real-word experience the effectiveness of dupilumab was excellent and resulted higher than that observed in clinical trials, with a good safety profile during COVID-19 pandemic.Keywords
This publication has 12 references indexed in Scilit:
- Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case SeriesActa Dermato-Venereologica, 2020
- Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic DermatitisJAMA Dermatology, 2020
- Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase II a open‐label trial and subsequent phase III open‐label extensionBritish Journal of Dermatology, 2019
- Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health‐related quality of life improvements and implications for treatment goalsBritish Journal of Dermatology, 2019
- Quality of Life of Parents of Children with Atopic DermatitisActa Dermato-Venereologica, 2017
- Suicidal Ideation, Mental Health Problems, and Social Function in Adolescents with Eczema: A Population-Based StudyJournal of Investigative Dermatology, 2014
- Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilizationPediatric Allergy and Immunology, 2013
- Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitisJournal of Allergy and Clinical Immunology, 2011
- Global variations in prevalence of eczema symptoms in children from ISAAC Phase ThreeJournal of Allergy and Clinical Immunology, 2009
- Changes in Prevalence of Asthma and Allergies Among Children and Adolescents in Italy: 1994–2002Pediatrics, 2006